CINCHOPHEN

US Previously Marketed

First marketed in 1908

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H11NO2
Molecular Weight	249.264
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=CC(=NC2=C1C=CC=C2)C3=CC=CC=C3

InChI

InChIKey=YTRMTPPVNRALON-UHFFFAOYSA-N

InChI=1S/C16H11NO2/c18-16(19)13-10-15(11-6-2-1-3-7-11)17-14-9-5-4-8-12(13)14/h1-10H,(H,18,19)

HIDE SMILES / InChI

Molecular Formula	C16H11NO2
Molecular Weight	249.264
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://jamanetwork.com/journals/jama/article-abstract/1156819
Curator's Comment: Description was created based on several sources, including http://www.un.org/esa/coordination/CL12.pdf

Cinchophen, phenylcinchoninic acid, seems to have been discovered in 1887 by Doebner and Gieseke and to have been introduced into medicine under the trade name of atophan in 1908 by Nicolaier and Dohrn. Since that time it has been used extensively for gout as well as for other forms of arthritis and for the relief of pain of all types. Use of Cinchophen in humans ceased in the 1930s due to the discovery that it can cause serious liver damage.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Proto-oncogene c-Fos 8 Target ID: P12841 Gene ID: 314322.0 Gene Symbol: Fos Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8981440	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Arthritis 87 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14890976	Palliative		Approved 8583	Atophan Approved Use It has been used extensively for gout as well as for other forms of arthritis and for the relief of pain of all types.

Doses

Dose	Population	Adverse events
485.9 mg 3 times / day multiple, oral Dose: 485.9 mg, 3 times / day Route: oral Route: multiple Dose: 485.9 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18741907	unhealthy, 19 years Health Status: unhealthy Age Group: 19 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/18741907	Other AEs: Jaundice, Nausea... Other AEs: Jaundice Nausea Abdominal pain Sources: https://pubmed.ncbi.nlm.nih.gov/18741907
485.9 mg 1 times / day multiple, oral Dose: 485.9 mg, 1 times / day Route: oral Route: multiple Dose: 485.9 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20778752	unhealthy, 38 years Health Status: unhealthy Age Group: 38 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/20778752	Disc. AE: Jaundice... AEs leading to discontinuation/dose reduction: Jaundice (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/20778752
300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1679861	unhealthy, 57 - 67 years Health Status: unhealthy Age Group: 57 - 67 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/1679861	Disc. AE: Hepatitis... Other AEs: Hepatic failure... AEs leading to discontinuation/dose reduction: Hepatitis (acute, 2 patients) Other AEs: Hepatic failure (severe\|grade 5, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/1679861
0.5 g 1 times / day multiple, oral Dose: 0.5 g, 1 times / day Route: oral Route: multiple Dose: 0.5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/13470708	unhealthy, 59 years Health Status: unhealthy Age Group: 59 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/13470708	Disc. AE: Hepatitis, Agranulocytosis... AEs leading to discontinuation/dose reduction: Hepatitis Agranulocytosis Sources: https://pubmed.ncbi.nlm.nih.gov/13470708

AEs

AE	Significance	Dose	Population
Abdominal pain		485.9 mg 3 times / day multiple, oral Dose: 485.9 mg, 3 times / day Route: oral Route: multiple Dose: 485.9 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18741907	unhealthy, 19 years Health Status: unhealthy Age Group: 19 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/18741907
Jaundice		485.9 mg 3 times / day multiple, oral Dose: 485.9 mg, 3 times / day Route: oral Route: multiple Dose: 485.9 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18741907	unhealthy, 19 years Health Status: unhealthy Age Group: 19 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/18741907
Nausea		485.9 mg 3 times / day multiple, oral Dose: 485.9 mg, 3 times / day Route: oral Route: multiple Dose: 485.9 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18741907	unhealthy, 19 years Health Status: unhealthy Age Group: 19 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/18741907
Jaundice	grade 5 Disc. AE	485.9 mg 1 times / day multiple, oral Dose: 485.9 mg, 1 times / day Route: oral Route: multiple Dose: 485.9 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20778752	unhealthy, 38 years Health Status: unhealthy Age Group: 38 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/20778752
Hepatitis	acute, 2 patients Disc. AE	300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1679861	unhealthy, 57 - 67 years Health Status: unhealthy Age Group: 57 - 67 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/1679861
Hepatic failure	severe\|grade 5, 1 patient	300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1679861	unhealthy, 57 - 67 years Health Status: unhealthy Age Group: 57 - 67 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/1679861
Agranulocytosis	Disc. AE	0.5 g 1 times / day multiple, oral Dose: 0.5 g, 1 times / day Route: oral Route: multiple Dose: 0.5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/13470708	unhealthy, 59 years Health Status: unhealthy Age Group: 59 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/13470708
Hepatitis	Disc. AE	0.5 g 1 times / day multiple, oral Dose: 0.5 g, 1 times / day Route: oral Route: multiple Dose: 0.5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/13470708	unhealthy, 59 years Health Status: unhealthy Age Group: 59 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/13470708

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
UGT1A1 246 UGT1A3 89 MRP2 499 OATP1B1 1079	UGT1A1 479 UGT1A3 470

Drug as perpetrator

Target	Modality	Activity
MRP2 625	inhibitor 4027 Sources: https://www.sygnaturediscovery.com/publications/posters/deciphering-mechanism-cinchophen-induced-liver-injury/	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.sygnaturediscovery.com/publications/posters/deciphering-mechanism-cinchophen-induced-liver-injury/	no
UGT1A1 303	inhibitor 4027 Sources: https://www.sygnaturediscovery.com/publications/posters/deciphering-mechanism-cinchophen-induced-liver-injury/	weak [IC50 3000 uM]
UGT1A3 99	inhibitor 4027 Sources: https://www.sygnaturediscovery.com/publications/posters/deciphering-mechanism-cinchophen-induced-liver-injury/	weak [IC50 3100 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
UGT1A1 479	substrate 4014 Sources: https://www.sygnaturediscovery.com/publications/posters/deciphering-mechanism-cinchophen-induced-liver-injury/	yes
UGT1A3 470	substrate 4014 Sources: https://www.sygnaturediscovery.com/publications/posters/deciphering-mechanism-cinchophen-induced-liver-injury/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChemIDplus	855165138	https://chem.nlm.nih.gov/chemidplus/id/0855165138
EPA DSSTox	DTXSID40234726	https://comptox.epa.gov/dashboard/DTXSID40234726
PubChem	71300650	https://pubchem.ncbi.nlm.nih.gov/compound/71300650
Wikidata	Q27285387

PubMed

Title	Date	PubMed
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.	2014-01	24085192
Bis(μ-2-phenyl-quinoline-4-carboxyl-ato)-κO,O':O;κO:O,O'-bis-[(2,2'-bipyridine-κN,N')(2-phenyl-quinoline-4-carboxyl-ato-κO,O')cadmium(II)].	2010-12-04	21522597
Poly[bis-(μ-hemihydrogen 2-phenyl-quinoline-4-carboxyl-ato-κN,O)silver(I)].	2009-01-23	21581814
Comprehensive screening and quantification of veterinary drugs in milk using UPLC-ToF-MS.	2008-07	18491081
Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase.	2005-03-15	15727850
A series of quinoline analogues as potent inhibitors of C. albicans prolyl tRNA synthetase.	2001-02-26	11229766

Patents

Sample Use Guides

In Vivo Use Guide

The mean dose was 300 mg/day for a mean duration of 3-4 months

Route of Administration: Unknown

In Vitro Use Guide

Cinchophen (200 ug /ml) reduced the response of the isolated guinea-pig ileum to bradykinin.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:45:07 GMT 2025` Edited by `admin` on `Mon Mar 31 17:45:07 GMT 2025`
Record UNII	39Y533Z02M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NSC-2617

Preferred Name

English

CINCHOPHEN

Official Name

English

CINCHOPHEN [MART.]

Common Name

English

CINCHOPHEN [MI]

Common Name

English

cinchophen [INN]

Common Name

English

PHENYLCINCHONINIC ACID

Systematic Name

English

2-PHENYLCINCHONINIC ACID

Systematic Name

English

CINCHOPHEN [HSDB]

Common Name

English

Cinchophen [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-ATC

M04AC02